Breaking News Instant updates and real-time market news.

ACN

Accenture

$207.64 /

+1.54 (+0.75%)

07:31
01/13/20
01/13
07:31
01/13/20
07:31

Accenture announces changes to growth model, global management committee

Accenture announced changes to its growth model and Global Management Committee, effective March 1, 2020. Accenture will organize its capabilities into four services: Strategy & Consulting, Interactive, Technology, and Operations. The company will manage its business through three geographic markets - North America, Europe, and Growth Markets - instead of operating groups. Accenture will continue to go to market by industry and will expand its global industry programs. At the same time, Accenture will be making leadership changes and expanding its Global Management Committee to include a broader representation of leaders from its services and geographic markets. Accenture is making these changes at a time of unprecedented change for its clients. Digital and technology are now core to their success, fueling the need for enterprise-wide transformation and continuous innovation, it said in a statement. "Accenture's formula for market leadership is enduring: We continually transform our business and embrace change to create value for our clients with incredibly talented people, including our deep bench of experienced leaders," said Julie Sweet, Accenture's chief executive officer. "The changes we are announcing today will unleash the full potential of the extraordinary capabilities we have built, create greater opportunities for our people, and act as a catalyst for us to again set the new standard in our industry." Accenture confirmed that there is no change to its business outlook for the second quarter and full fiscal year 2020 that the company provided as part of its first-quarter fiscal 2020 earnings announcement on Dec. 19, 2019.

  • 16

    Jan

  • 10

    Feb

ACN Accenture
$207.64 /

+1.54 (+0.75%)

01/07/20 MOFT
Accenture downgraded to Neutral from Buy at MoffettNathanson
01/07/20 MOFT
Accenture downgraded to Neutral from Buy at MoffettNathanson
01/07/20
Fly Intel: Top five analyst downgrades
01/09/20 WELS
Accenture price target raised to $230 from $225 at Wells Fargo

TODAY'S FREE FLY STORIES

Hot Stocks
Sprint reports Q3 postpaid wireless service revenue $4.2B » 08:03
01/27/20
01/27
08:03
01/27/20
08:03
S

Sprint

$4.83 /

-0.2 (-3.98%)

Postpaid wireless service…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Select Medical sees FY20 EPS $1.27-$1.46, consensus $1.33 » 08:03
01/27/20
01/27
08:03
01/27/20
08:03
SEM

Select Medical

$23.87 /

-0.62 (-2.53%)

Sees FY20 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Jefferies starts Elbit Systems at Buy with $185 price target » 08:02
01/27/20
01/27
08:02
01/27/20
08:02
ESLT

Elbit Systems

$153.84 /

-0.11 (-0.07%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Commodity Markets Council to hold a conference » 08:02
01/27/20
01/27
08:02
01/27/20
08:02
CME

CME Group

$209.27 /

+1.02 (+0.49%)

, ICE

IntercontinentalExchange

$97.11 /

-0.2 (-0.21%)

State of the Industry…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler to host company meetings at conference » 08:01
01/27/20
01/27
08:01
01/27/20
08:01
LEG

Leggett & Platt

$50.90 /

-0.4 (-0.78%)

, TPX

Tempur Sealy

$87.31 /

-0.73 (-0.83%)

Piper Sandler Hosted…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Sprint reports Q3 EPS (3c), consensus (5c) » 08:01
01/27/20
01/27
08:01
01/27/20
08:01
S

Sprint

$4.83 /

-0.2 (-3.98%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Korn/Ferry management to meet with Sidoti » 08:01
01/27/20
01/27
08:01
01/27/20
08:01
KFY

Korn/Ferry

$43.03 /

-0.59 (-1.35%)

Meeting to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Canaccord upgrades Biogen to Buy on 'decent shot' of Alzheimer's approval » 08:01
01/27/20
01/27
08:01
01/27/20
08:01
BIIB

Biogen

$278.14 /

-6.11 (-2.15%)

Canaccord Genuity analyst…

Canaccord Genuity analyst Sumant Kulkarni upgraded Biogen to Buy from Hold with a price target of $360, up from $305. The shares closed Friday down 2% to $278.14. The analyst admits to being "surprised as anyone" by Biogen's "sudden revival" in October of aducanumab for early Alzheimer's disease. Kulkarni, who retains a "healthy degree of skepticism" around the trial data Biogen presented in December, says that even skeptics appear to agree that aducanumab, "for a variety of reasons, has a decent shot at FDA approval." This is not reflected in the shares at current levels, Kulkarni tells investors in a research note. The analyst likes the opportunity Biogen presents heading into the "regulatory saga" on aducanumab. His new price target reflects a 50% probability of approval for aducanumab.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Deckers Brands sentiment remains positive, says Baird » 08:01
01/27/20
01/27
08:01
01/27/20
08:01
DECK

Deckers Brands

$177.84 /

+2.75 (+1.57%)

Baird analyst Jonathan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Drug Information Association to hold a conference » 08:00
01/27/20
01/27
08:00
01/27/20
08:00
ABBV

AbbVie

$83.53 /

-1.73 (-2.03%)

, ALLO

Allogene Therapeutics

$23.43 /

-1.29 (-5.22%)

, ALXN

Alexion

$105.24 /

-3.3 (-3.04%)

, BMY

Bristol-Myers

$64.18 /

-2.715 (-4.06%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, CRBP

Corbus Pharmaceuticals

$6.73 /

-0.29 (-4.13%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXPO

Exponent

$72.45 /

-0.9 (-1.23%)

, GSK

GlaxoSmithKline

$47.24 /

-0.605 (-1.26%)

, HALO

Halozyme

$19.07 /

-0.58 (-2.95%)

, IQV

Iqvia

$158.14 /

-2.735 (-1.70%)

, LLY

Eli Lilly

$139.09 /

-2.14 (-1.52%)

, PFE

Pfizer

$39.82 /

-0.89 (-2.19%)

Pharmacovigilance &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
FTC grants early termination of HSR Act waiting period for Achillion sale » 08:00
01/27/20
01/27
08:00
01/27/20
08:00
ACHN

Achillion

$6.14 /

-0.025 (-0.41%)

, ALXN

Alexion

$105.24 /

-3.3 (-3.04%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Apple put buyer realizes 34% same-day gains » 08:00
01/27/20
01/27
08:00
01/27/20
08:00
AAPL

Apple

$318.25 /

-1.02 (-0.32%)

Notable profits for the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
BBX Capital management to meet with Sidoti » 07:59
01/27/20
01/27
07:59
01/27/20
07:59
BBX

BBX Capital

$4.07 /

-0.05 (-1.21%)

Meeting to be held in New…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
American Hotel & Lodging Association to hold a summit » 07:59
01/27/20
01/27
07:59
01/27/20
07:59
AAL

American Airlines

$27.66 /

-1.14 (-3.96%)

, ACCYY

Accor

$0.00 /

+ (+0.00%)

, CBRE

CBRE Group

$60.78 /

-0.065 (-0.11%)

, DRH

DiamondRock

$10.13 /

-0.305 (-2.92%)

, PEB

Pebblebrook Hotel

$24.64 /

-0.455 (-1.81%)

, WH

Wyndham Hotels & Resorts

$58.58 /

-0.84 (-1.41%)

Americas Lodging…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Jefferies starts Relmada at Buy, sees 50-100% upside potential » 07:58
01/27/20
01/27
07:58
01/27/20
07:58
RLMD

Relmada Therapeutics

$43.00 /

+2.5 (+6.17%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
International Market Centers to hold a conference » 07:58
01/27/20
01/27
07:58
01/27/20
07:58

2020 Winter Las Vegas…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Goldman Sachs to host investor day » 07:58
01/27/20
01/27
07:58
01/27/20
07:58
GS

Goldman Sachs

$241.87 /

-3.78 (-1.54%)

Investor day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Coronavirus could be 3%-5% EPS hit for China-exposed stocks, says Credit Suisse » 07:56
01/27/20
01/27
07:56
01/27/20
07:56
EL

Estee Lauder

$205.32 /

-3.47 (-1.66%)

, NKE

Nike

$102.03 /

-0.98 (-0.95%)

, TPR

Tapestry

$27.29 /

-0.635 (-2.27%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Nordson upgraded to Buy from Neutral at DA Davidson » 07:56
01/27/20
01/27
07:56
01/27/20
07:56
NDSN

Nordson

$171.20 /

-1.1 (-0.64%)

DA Davidson analyst Matt…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Kinder Morgan to host analyst meeting » 07:54
01/27/20
01/27
07:54
01/27/20
07:54
KMI

Kinder Morgan

$21.56 /

-0.21 (-0.96%)

Analyst meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Scorpio Bulkers reports Q4 adjusted EPS 57c, may not compare to consensus 0c » 07:53
01/27/20
01/27
07:53
01/27/20
07:53
SALT

Scorpio Bulkers

$4.52 /

-0.19 (-4.03%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Novavax platform ideally suited for pandemic flu outbreaks, says Ladenburg » 07:53
01/27/20
01/27
07:53
01/27/20
07:53
NVAX

Novavax

$7.80 /

+0.16 (+2.09%)

Novavax has experience in…

Novavax has experience in developing coronavirus vaccines and its insect-based vaccine platform is ideally suited to address pandemic flu outbreaks, Ladenburg analyst Michael Higgins tells investors in a research note. It is possible for the company to develop a 2019 coronavirus vaccine that is ready for manufacturing scale-up in 90 days, but it's still likely that any regulatory clearance would require toxicity and stability studies, plus animal studies, before any human testing could begin, adds Higgins, citing his talks with management. He believes Novavax's fundamental driver continues to be NanoFlu, with pivotal results expected in late March. NanoFlu's potential seasonal flu revenues remain the analyst's only source of Novavax projected revenues. He continues to model $1B in 2027 revenues following a launch in the 2022/2023 flu season. Higgins keeps a Buy rating on Novavax shares with a $27.50 price target. The stock closed Friday up 14c to $7.80 and is rallyig $1.35 to $9.15 in premarket trading amid reports of the spreading coronavirus.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
BeiGene price target lowered to $200 from $216 at Cowen » 07:52
01/27/20
01/27
07:52
01/27/20
07:52
BGNE

BeiGene

$163.41 /

-5.77 (-3.41%)

Cowen analyst Yaron…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Sempra Energy management to meet with UBS » 07:51
01/27/20
01/27
07:51
01/27/20
07:51
SRE

Sempra Energy

$159.76 /

-0.32 (-0.20%)

Meeting to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
Treasury Market Outlook: equities have plunged and yields have richened » 07:50
01/27/20
01/27
07:50
01/27/20
07:50

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.